Indegene Ltd released its financial results for the fourth quarter of FY25 on Monday, April 28, 2025.
In Indegene Q4 results, the company posted a consolidated net profit of ₹117.6 crore. This marks a 24% year-on-year (YoY) rise from ₹94.8 crore reported in the same quarter of the previous fiscal year.
For the final quarter of FY25, Indegene Ltd recorded a 12.3% YoY growth in its revenue from operations, reaching ₹755.6 crore, up from ₹673 crore in the corresponding quarter last year.
Furthermore, Indegene latest results revealed a 16.7% growth in its diluted EPS, which increased to ₹4.9 in Q4 FY25, an improvement from ₹4.2 reported in the same period the previous year.
Indegene Ltd. Q4 Results Highlights
In this table, you will get an overview of Indegene latest quarterly results:
| Q4 FY2024-25 | Q3 FY2024-25 | Q4 FY2023-24 | YoY Growth (%) | QoQ Growth (%) | |
| Total Income (₹ in crore) | ₹781.2 | ₹758.1 | ₹696.2 | 12.2% | 3% |
| Net profit (₹ in crore) | ₹117.6 | ₹109.7 | ₹94.8 | 24% | 7.2% |
| EPS (Diluted) | ₹4.9 | ₹4.6 | ₹4.2 | 16.7% | 6.5% |
Indegene Ltd’s Financial Results Comparison with the Previous Year
Here is a table of annual data comparison of Indegene Q4 2025 results:
| FY 2024-25 | FY 2023-24 | |
| Total Income (in crore) | ₹2,946.5 | ₹2,666 |
| Net profit (in crore) | ₹406.7 | ₹336.7 |
| EPS | ₹17 | ₹15 |
Updates Shared by Indegene in Latest Financial Results
During the announcements of Indegene Q4 results, the company’s management provided key updates regarding the upcoming quarters:
-
100% Dividend Announced
In Q4 Indegene results, the company recommended a final dividend of ₹2 per equity share (face value ₹2) for the financial year ended March 31, 2025.
The dividend will be paid within 30 days following shareholder approval at the upcoming Annual General Meeting (AGM). The record date and AGM date will be announced later.
-
Initial Public Offering (IPO) Highlights
During the year, the company filed its IPO of 40,766,550 equity shares (face value ₹2 each) at an issue price of ₹452 per share.
This included a fresh issue of 16,833,818 shares (raising ₹7,600 crore) and an offer for sale of 23,932,732 shares (₹10,818 crore) by selling shareholders.
The equity shares were listed on NSE and BSE on May 13, 2024. The Company received ₹7,244 crore (net of IPO expenses of ₹356), with ₹319 crore of the adjusted costs against the securities premium.
-
Utilisation of IPO Proceeds
The Company has repaid a loan of $47.20 million (₹3,950 crore) on behalf of its material subsidiary, ILSL Holdings Inc., thereby fulfilling Objective 1 outlined in the offer document.
The repayment amount exceeded the specified limit due to exchange rate fluctuations.
As of March 31, 2025, unutilised net proceeds include ₹980 crore invested in fixed deposits, ₹41 crore held in the company’s monitoring account, and the remaining balance retained in the public offer account for pending issue-related expenses.
-
Employee Stock Options and Grants
According to Indegene Q4 results, the company granted a total of 521,330 options under the Employee Restricted Stock Unit Plan 2020 (RSU 2020), 243,973 options under the Employee Stock Option Plan 2020 (ESOP 2020), and 39,571 options under the Company Share Option Plan 2022 (CSOP 2022) to eligible employees.
Additionally, 527,331 options under the RSU 2020 plan and 211,722 options under the ESOP 2020 plan were exercised during the year.
-
Acquisition of MJL Communications Group Ltd.
In the latest Indegene results, the group said that it acquired 100% of MJL Communications Group Ltd for ₹398 crore, including an earnout payment of ₹149 crore.
MJL specialises in brand strategy and healthcare communications. The contingent consideration ranges from Nil to ₹172 crore, based on performance from April 2025 to March 2027.
To get the latest and helpful updates on financial results, geopolitical developments, and market insights regularly, follow Torus Digital!
